SpringWorks Therapeutics Completes Submission of New Drug Application to the FDA for Mirdametinib for the Treatment of Children and Adults with NF1-PN
July 01, 2024 06:30 ET
|
SpringWorks Therapeutics, Inc.
STAMFORD, Conn., July 01, 2024 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, announced...
SpringWorks Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
June 05, 2024 07:00 ET
|
SpringWorks Therapeutics, Inc.
STAMFORD, Conn., June 05, 2024 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, today...
SpringWorks Therapeutics Announces Data to be Presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
May 23, 2024 17:13 ET
|
SpringWorks Therapeutics, Inc.
– Results from pivotal Phase 2b ReNeu trial of mirdametinib in patients with NF1-PN to be presented in an oral presentation – – Additional data and analyses from Phase 3 DeFi trial of OGSIVEO®...
SpringWorks Therapeutics to Participate in the BofA Securities 2024 Health Care Conference
May 08, 2024 07:00 ET
|
SpringWorks Therapeutics, Inc.
STAMFORD, Conn., May 08, 2024 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, today...
SpringWorks Therapeutics Reports First Quarter 2024 Financial Results and Highlights Recent Business Updates
May 02, 2024 06:30 ET
|
SpringWorks Therapeutics, Inc.
– Achieved $21.0 million in OGSIVEO® (nirogacestat) net product revenue in the first quarter – – Received validation from the EMA for MAA of nirogacestat for the treatment of adults with desmoid...
SpringWorks Therapeutics Announces Abstracts Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
April 24, 2024 13:31 ET
|
SpringWorks Therapeutics, Inc.
– Results from Phase 2b ReNeu trial of mirdametinib in NF1-PN accepted for oral presentation –– Additional data from the Phase 3 DeFi trial of OGSIVEO® (nirogacestat) in adults with desmoid...
SpringWorks Therapeutics to Report First Quarter 2024 Financial Results Thursday, May 2, 2024
April 18, 2024 07:00 ET
|
SpringWorks Therapeutics, Inc.
STAMFORD, Conn., April 18, 2024 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, today...
SpringWorks Therapeutics Initiates Rolling Submission of New Drug Application to the FDA for Mirdametinib for the Treatment of Children and Adults with NF1-PN
March 04, 2024 06:30 ET
|
SpringWorks Therapeutics, Inc.
STAMFORD, Conn., March 04, 2024 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, announced...
SpringWorks Therapeutics Announces European Medicines Agency Validation for Marketing Authorization Application of Nirogacestat for the Treatment of Adults with Desmoid Tumors
February 29, 2024 08:30 ET
|
SpringWorks Therapeutics, Inc.
STAMFORD, Conn., Feb. 29, 2024 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, announced...
SpringWorks Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Business Updates
February 27, 2024 06:30 ET
|
SpringWorks Therapeutics, Inc.
– Reported OGSIVEO™ (nirogacestat) net product revenue of $5.4 million in first partial quarter of launch following FDA approval on November 27, 2023 – – Submitted Marketing Authorization Application...